Asked by: Norman Lamb (Liberal Democrat - North Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many meetings he held with his Department’s Chief Scientific Adviser between 1 March 2019 and 31 May 2019.
Answered by Caroline Dinenage
For the period 1 March 2019 and 31 May 2019 my Rt. hon. Friend the Secretary of State for Health and Social Care met the Department’s Chief Scientific Adviser seven times.
Asked by: Norman Lamb (Liberal Democrat - North Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much was money was spent by (a) NHS England, (b) NHS Trusts, (c) Health Education England and (d) NHS Improvement on the services of (a) Bevan Brittan, (b) Mills & Reeve, (c) DAC Beechcroft, (d) Hempsons, (e) Capsticks and (f) Hill Dickinson in relation to employment and whistleblower disputes in each of the last five years.
Answered by Caroline Dinenage
The arm’s length bodies concerned do not collect information in a way that would enable them to answer this question in the format requested.
Asked by: Norman Lamb (Liberal Democrat - North Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when his Department plans to publish data on the uptake of influenza vaccinations by social care workers in 2018-19.
Answered by Seema Kennedy
There is no nationally agreed data set or data collection for recording the immunisation of social care workers.
Asked by: Norman Lamb (Liberal Democrat - North Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the average weekly fee per patient charged to the NHS was for the provision of care by Cygnet at Whorlton Hall.
Answered by Caroline Dinenage
This information is not held centrally.
Asked by: Norman Lamb (Liberal Democrat - North Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to his oral contribution on 26 March 2019 to Question 910028 on Antimicrobial Resistance: Vaccines, what steps his Department is taking to stimulate research and development into vaccines, including for tuberculosis, as an alternative to antibiotics.
Answered by Seema Kennedy
The United Kingdom national action plan on antimicrobial resistance (AMR), published on 24 January 2019, contains the commitment to continue to support research into new and alternative treatments, vaccines and diagnostic tests.
The Government has invested over £350 million in AMR research and development since 2014, including research funding calls with vaccination in scope, most recently the £32 million capital funding call lead by the National Institute for Health Research (NIHR), and the Small Business Research Initiative competition which announced its awards in January 2019. We would expect to consider the role of vaccines for AMR in future programmatic funding.
The UK supports the development of vaccines through UK Aid programmes such as the Global AMR Innovation Fund (GAMRIF) and the UK Vaccine Network. GAMRIF is a £50 million fund to support innovative research and development for AMR, for the benefit of people in low- and middle-income countries, and invests £30 million into preventative measures in human and animal health, including vaccines for AMR not including tuberculosis (TB). The fund includes a £1 million work package with the Bacterial Vaccinology Network which supports early stage research and development around the world to drive the development and uptake of vaccines for AMR in humans and animals.
The UK supports TB vaccine research through the Medical Research Council (MRC), with support to the European and Developing Countries Clinical Trials Partnership, and through the Joint Global Health Clinical Trials programme represented by the Department for International Development (DFID), MRC, NIHR and Wellcome. DFID’s Agriculture research team is supporting work on bovine TB vaccine development in partnership with the Bill and Melinda Gates Foundation.
Asked by: Norman Lamb (Liberal Democrat - North Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to his oral contribution on 26 March 2019 to Question 910028 on Antimicrobial Resistance: Vaccines, what funding he plans to make to stimulate research and development into vaccines as an alternative to antibiotics.
Answered by Seema Kennedy
The United Kingdom national action plan on antimicrobial resistance (AMR), published on 24 January 2019, contains the commitment to continue to support research into new and alternative treatments, vaccines and diagnostic tests.
The Government has invested over £350 million in AMR research and development since 2014, including research funding calls with vaccination in scope, most recently the £32 million capital funding call lead by the National Institute for Health Research (NIHR), and the Small Business Research Initiative competition which announced its awards in January 2019. We would expect to consider the role of vaccines for AMR in future programmatic funding.
The UK supports the development of vaccines through UK Aid programmes such as the Global AMR Innovation Fund (GAMRIF) and the UK Vaccine Network. GAMRIF is a £50 million fund to support innovative research and development for AMR, for the benefit of people in low- and middle-income countries, and invests £30 million into preventative measures in human and animal health, including vaccines for AMR not including tuberculosis (TB). The fund includes a £1 million work package with the Bacterial Vaccinology Network which supports early stage research and development around the world to drive the development and uptake of vaccines for AMR in humans and animals.
The UK supports TB vaccine research through the Medical Research Council (MRC), with support to the European and Developing Countries Clinical Trials Partnership, and through the Joint Global Health Clinical Trials programme represented by the Department for International Development (DFID), MRC, NIHR and Wellcome. DFID’s Agriculture research team is supporting work on bovine TB vaccine development in partnership with the Bill and Melinda Gates Foundation.
Asked by: Norman Lamb (Liberal Democrat - North Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much the East of England Ambulance Service NHS Trust spent on legal fees on its appeal to the First Tier Tribunal with respect to the Information Commissioner's Office's decision notices on patient safety and welfare information.
Answered by Stephen Hammond
The East of England Ambulance Service NHS Trust spent £4,655.29 on legal fees on its appeal to the First Tier Tribunal with respect to the Information Commissioner's Office's decision notices on patient safety and welfare information.
The amount East of England Ambulance Service NHS Trust has spent on legal fees defending employment tribunal cases in each year since 2016 is set out in the following table.
Year | Amount |
2016/17 | £267,037.81 |
2017/18 | £213,414.20 |
2018/19 | £325,640.03 (year to date) |
Asked by: Norman Lamb (Liberal Democrat - North Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much the East of England Ambulance Service NHS Trust spent on legal fees defending employment tribunal cases in each year since 2016.
Answered by Stephen Hammond
The East of England Ambulance Service NHS Trust spent £4,655.29 on legal fees on its appeal to the First Tier Tribunal with respect to the Information Commissioner's Office's decision notices on patient safety and welfare information.
The amount East of England Ambulance Service NHS Trust has spent on legal fees defending employment tribunal cases in each year since 2016 is set out in the following table.
Year | Amount |
2016/17 | £267,037.81 |
2017/18 | £213,414.20 |
2018/19 | £325,640.03 (year to date) |
Asked by: Norman Lamb (Liberal Democrat - North Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many meetings he held with his Department’s Chief Scientific Adviser between 1 December 2018 and 28 February 2019.
Answered by Caroline Dinenage
For the period 1 December 2018 and 28 February 2019, my Rt. hon. Friend the Secretary of State for Health and Social Care met with the Department’s Chief Scientific Adviser (CSA) seven times, and the CSA met with other Health and Social Care ministers on 12 occasions.
Asked by: Norman Lamb (Liberal Democrat - North Norfolk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much each NHS trust spent on legal fees defending employment tribunal cases relating to (a) discrimination, (b) unfair dismissal and (c) public interest disclosure in each year since 2016.
Answered by Stephen Hammond
Costs for how much each National Health Service trust spent in legal fees defending employment tribunal cares relating to discrimination, unfair dismissal and public interest disclosure since 2016 is not held centrally.